Rivastigmine in the treatment of patients with Alzheimer’s disease

نویسنده

  • Thomas Müller
چکیده

Impairment of attention and memory in patients with Alzheimer's disease (AD) is associated with significantly lower levels of acetylcholine. Inhibition of the breakdown of acetylcholine by blocking the enzymes acetylcholinesterase and butyrylcholinesterase with rivastigmine improves this cholinergic depletion. Thus rivastigmine administration provides established, effective, long-term symptomatic treatment in AD and Parkinson's disease (PD) patients with dementia. A sustained treatment with cholinesterase inhibitors in general may also induce a certain deterioration of fine motor behavior, which may play a crucial role in the treatment of PD patients with dementia. Recent studies show that this altered balance between dopamine and acetylcholine due to cholinesterase inhibition, with its possible negative impact on motion behaviour, does not present a major problem in clinical practice in AD patients and may be compensated for by modification of dopaminergic substitution in PD patients with dementia. However, progression of neurodegeneration increases the vulnerability for psychosis in AD and PD patients with dementia in combination with dehydration and often requires additional application of neuroleptics. Since classical neuroleptics increase extrapyramidal symptoms, atypical neuroleptics are used. Out of these, quetiapine shows a distinct lower anticholinergic (muscarinergic) potency with beneficial effects on cognition. This favors its use in combination with rivastigmine.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Ultrasonic Irradiation Assisted Enantioselective Synthesis of Alzheimer’s Disease Drug Rivastigmine Tartrate by Using Nanocatalyst

A highly efficient and convenient procedure for the enantioselective synthesis of (S)-Rivastigmine tartrate, a cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s disease, is accomplished by the treatment of versatile, readily accessible N-Ethyl-N-methyl carbamoyl chloride with 3-hydroxyacetophenone under ultrasonic irradiation in presence of nano-K2CO3 were repo...

متن کامل

Piracetam, Rivastigmine and Their Joint Consumption Effects on MMSE Score Status in Patients with Alzheimer's Disease

Alzheimer's disease is considered the most common cause of dementia. At present, no definite cure is available for healing the disorders and stopping the disease progress. The aim of this study is to study the effects of piracetam, rivastigmine and their joint consumption on MMSE score status in patients with Alzheimer disease. This interventional study was carried out on 64 patients with ...

متن کامل

Is Rivastigmine Effective in the Treatment of Alzheimer’s Disease?

OBJECTIVE: The objective of this selective EBM review is to determine whether or not rivastigmine is effective for the treatment of Alzheimer’s Disease. STUDY DESIGN: Review of two trials in the English language published in 2007 and 2010, and an open-label, singlearm, multi-center study from 2008. DATA SOURCES: Randomized, double-blind, placebo-controlled trials comparing rivastigmine to a vis...

متن کامل

Donepezil and Rivastigmine: Pharmacokinetic Profle and Brain-targeting After Intramuscular Administration in Rats

Current palliative pharmacotherapy of Alzheimer’s disease based on the cholinergic hypothesisled to the development of four cholinesterase inhibitors. These compounds can bring prolongationof the symptom-free period in some patients. This is the frst report directly comparing donepeziland rivastigmine plasma and brain levels in <span class="font...

متن کامل

Donepezil and Rivastigmine: Pharmacokinetic Profle and Brain-targeting After Intramuscular Administration in Rats

Current palliative pharmacotherapy of Alzheimer’s disease based on the cholinergic hypothesisled to the development of four cholinesterase inhibitors. These compounds can bring prolongationof the symptom-free period in some patients. This is the frst report directly comparing donepeziland rivastigmine plasma and brain levels in <span class="font...

متن کامل

High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease.

To the Editor: Cholinesterase inhibitors are widely accepted as established therapeutic intervention across the entire severity spectrum of Alzheimer’s disease. However, fear of increased corrected QT interval (QTc) time is one of the main reasons for nonprescription of cholinergic drugs.1 While it is generally accepted that therapeutic efficacy of cholinergic therapy is dose dependent, a large...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Neuropsychiatric Disease and Treatment

دوره 3  شماره 

صفحات  -

تاریخ انتشار 2007